Showing 2644 results
- Media Release /68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1 Sustained clinical benefit from…
- Story /
The most lethal strain could be eliminated by 2030, but major hurdles remain.
- Featured News /
Latest oncology resources and news surrounding Novartis data featured at American Society of Clinical Oncology (ASCO)
- Media Release /Multidisciplinary Steering Committee established to drive action includes patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders Action Plan will provide roadmap…
- Featured News /
As a company, we stand up for greater inclusion of LGBTI people because when each of us feels included, we all benefit.
- Statement /
Novartis condemns the war in Ukraine and has been providing humanitarian support, financial donations as well as considerable volumes of medicines to those people impacted by the war.
- Featured News /
Novartis is committed to reimagining the fight against Chagas Disease and advocating for an integrated, end-to-end care approach.
- Media Release /Six African nations will join a partnership pioneered in Ghana using technology to track and better tackle sickle cell disease (SCD) Includes expanded rollout of an app to track babies diagnosed…
- Media Release /Kisqali is the only CDK4/6 inhibitor with consistent overall survival (OS) benefit seen across all three Phase III trials, with the longest median OS benefit ever reported for HR+/HER2- mBC1-10 OS…
- Media Release /Biomarker analysis from Phase III SOLAR-1 study shows Piqray plus fulvestrant had clinical benefit regardless of presence of ESR1 mutations and genes implicated in CDK4/6i resistance1 Piqray plus…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 265
- › Next page